This 20 amino acid peptide binds to the amyloid form of beta-Amyloid (1-40) but not to monomeric beta-Amyloid (1-40). This sequence represents new potential carrier molecules to deliver medicines to amyloid plaques in AD patients and to image plaques in AD brains. The ability to directly target reagents to the amyloid form of the beta-Amyloid peptide may allow the delivery of neuroprotective agents to make amyloid plaques less toxic, the delivery of amyloid-destroying molecules to eliminate plaques, or the delivery of reagents to prevent amyloid plaque formation. This sequence is biotinylated on the N-terminus.

95%